Improvement of overall survival in advanced stage mantle cell lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 511-518

  Herrmann, Annina ^a   Hoster, Eva ^a   Zwingers, Thomas ^a   Brittinger, Günter ^a   Engelhard, Marianne ^a   Meusers, Peter ^a   Reiser, Marcel ^a   Forstpointner, Roswitha ^a   Metzner, Bernd ^a   Peter, Norma ^a   Wörmann, Bernhard ^a   Trümper, Lorenz ^a   Pfreundschuh, Michael ^a   Einsele, Hermann ^a   Hiddemann, Wolfgang ^a   Unterhalt, Michael ^a   Dreyling, Martin ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 59149105528     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.8435     Document Type: Article

References (29)

1. Brittinger G, Bartels H, Common H, et al: Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2:269-306, 1984
2. Oinonen R, Franssila K, Teerenhovi L, et al: Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients. Eur J Cancer 34:329-336, 1998
3. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
4. Hiddemann W, Unterhalt M, Herrmann R, et al: Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16:1922-1930, 1998
5. Devesa SS, Fears T: Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 52:5432s-5440s, 1992
6. Sant M, Allemani C, De Angelis R, et al: EUROCARE-3 Working Group: Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 44:579-587, 2008
7. Knospe WH, Loeb V Jr, Huguley CM Jr: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 33:555-562, 1974
8. Bagley CM Jr, Devita VT Jr, Berard CW, et al: Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76:227-234, 1972
9. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
10. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
11. Herold M, Pasold R, Srock S, et al: Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (RMCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 104:584a, 2004 (suppl. 1)
12. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007
13. Dreyling M, Weigert O, Hiddemann W: Current treatment standards and future strategies in mantle cell lymphoma. Ann Onc 19:iv41-iv44, 2008 (suppl 4)
14. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005
15. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
16. Ritchie DS, Seymour JF, Grigg AP, et al: The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 86:101-105, 2007
17. Till BG, Gooley TA, Crawford N, et al: Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leukemia Lymphoma 29:1-12, 2008
18. Dreyling M: Hyper-CVAD in mantle-cell lymphoma: Really "hyper" or just hype? Leuk Lymphoma 1-2, 2008
19. Khouri IF, Lee MS, Saliba RM, et al: Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407-4412, 2003
20. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
21. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
22. Jaffe ES, Harris NL, Stein H, et al: World Health Organisation classification of tumours: Pathology and genetics of haematopoetic and lymphoid tissues. Lyon, France, IARC Press, 2001
23. Nickenig C, Dreyling M, Hoster E, et al: Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107:1014-1022, 2006
24. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
25. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
26. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
27. Tiemann M, Schrader C, Klapper W, et al: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): A clinicopathological study from the European MCL Network. Br J Haematol 131:29-38, 2005
28. Callea V, Clo V, Morabito F, et al: Retrospective analysis of mantle cell lymphoma: Experience of the "Gruppo Italiano per lo Studio dei Linfomi" (GISL). Haematologica 83:993-997, 1998
29. Federal Statistical Office Germany. Wiesbaden, Germany, 2003